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Background. Leptin is an adipose tissue-derived hormone shown to be related to several metabolic, inﬂammatory, and hemostatic
factors related to chronic kidney disease. Recent animal studies have reported that infusion of recombinant leptin into normal
rats for 3 weeks fosters the development of glomerulosclerosis. However, few studies have examined the association between
leptin and CKD in humans. Therefore, we examined the association between plasma leptin levels and CKD in a representative
sample of US adults. Methods. We examined the third National Health and Nutrition Examination Survey participants >20 years
of age (n = 5820, 53.6% women). Plasma leptin levels were categorized into quartiles (≤4.3Fg/L, 4.4–8.7Fg/L, 8.8–16.9Fg/L,
>16.9Fg/L). CKD was deﬁned as a glomerular ﬁltration rate of <60mL/min/1.73m2 estimated from serum creatinine. Results.
Higher plasma leptin levels were associated with CKD after adjusting for age, sex, race/ethnicity, education, smoking, alcohol
intake, body mass index (BMI), diabetes, hypertension, and serum cholesterol. Compared to quartile 1 of leptin (referent), the
odds ratio (95% conﬁdence interval) of CKD associated with quartile 4 was 3.31 (1.41 to 7.78); P-trend = 0.0135. Subgroup
analyses examining the relation between leptin and CKD by gender, BMI categories, diabetes, and hypertension status also showed
a consistent positive association. Conclusion. Higher plasma leptin levels are associated with CKD in a representative sample of US
adults.
1.Introduction
Leptin is an adipose tissue-derived hormone that has been
shown to be related to several metabolic, inﬂammatory, and
hemostatic factors involved in the development of hyper-
tension and cardiovascular disease [1]. Experimental animal
studies suggest that higher leptin levels may cause hyper-
glycemia, elevations in blood pressure (mediated through
increasedsympatheticactivity),andrenaldysfunction[2].In
rat models, leptin has been shown to induce natriuresis [3]
which may in turn result in an increase in arterial pressure
so as to maintain sodium and water balance [4]. Leptin has
alsobeenshowntoserveasacofactorofTGF-betaactivation,
promote renal endothelial cell proliferation, and potentially
may play a role in renal glomerulosclerosis [5–7]. Recent
studies have reported that infusion of recombinant leptin
into normal rats for 3 weeks fosters the development of focal
glomerulos 4.clerosis [5]. However, few human studies have
examined the putative association between plasma leptin
levels and chronic kidney disease (CKD) in humans. In
this context, we examined the independent relation between
plasma leptin levels and CKD in a multiethnic sample of US
adults, after adjusting for main confounding factors.
2. Methods
The current study is based on data from the Third National
Health and Nutrition Examination Survey (NHANES III).2 International Journal of Nephrology
Detailed description of NHANES III study design and
methods are available elsewhere [8–13]. In brief, NHANES
III included a stratiﬁed multistage probability sample repre-
sentative of the civilian noninstitutionalized US population.
Selection was based on counties, blocks, households, and
individuals within households and included the oversam-
pling of non-Hispanic blacks and Mexican Americans in
order to provide stable estimates of these groups. Subjects
were required to sign a consent form before their participa-
tion, and approval was obtained from the Human Subjects
Committee in the US Department of Health and Human
Service. Secondary data analysis was approved by the West
Virginia University Institutional Review Board.
The sample included in the current analysis consisted of
participants aged greater than 20 years who were randomly
assigned to complete an examination in the morning after
an overnight fast. Plasma leptin levels were measured in
6415 of these participants. We further excluded participants
with self-reported cardiovascular disease (n = 434), missing
serum creatinine (n = 60) or who were missing data (n =
101) on covariates included in the multivariable model,
including systolic or diastolic blood pressure, body mass
index (BMI), or cholesterol levels. This resulted in 5820
participants (53.6% women).
2.1.MainOutcomeofInterest:PresenceofChronicKidneyDis-
ease. Serum creatinine was measured using the Jaﬀe kinetic
alkaline picrate method performed on a Roche Hitachi 737
analyzer[13].Thelaboratorycoeﬃcientofvariability ranged
from 0.2% to 1.4%. Serum creatinine values in NHANES
III were calibrated to the standard creatinine values from
the Cleveland Clinic Foundation (CCF) laboratory who
used a Roche coupled enzymatic assay method that was
traceable to an isotope dilution mass spectrometric method
using the following Deming regression equation: Standard
Creatinine in mg/dL = 0.960 × NHANES measured serum
creatinine (inmg/dL)–0.184 [14]. Glomerular ﬁltration rate
(eGFR) was estimated from serum creatinine using the 4-
variable Modiﬁcation of Diet in Renal Disease (MDRD)
study equation as follows: eGFR =175 × (serum creatinine
in mg/dL)−1.154× (age in years)−0.203× (0.742 if female)
× ( 1 . 2 1i fb l a c k )[ 15]. CKD was deﬁned as an eGFR
of <60mL/min/1.73m2, consistent with National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI) ≥ Stage 3 chronic kidney disease [16].
2.2. Exposure Measurements. Age, gender, race/ethnicity,
smoking status, alcohol intake (g/day), level of education,
history of diabetes and oral hypoglycemic intake or insulin
administration, and antihypertensive medication use were
assessed using standardized questionnaires. Individuals who
had not smoked ≥100 cigarettes in their lifetimes were
considered never smokers; those who had smoked ≥100
cigarettes in their lifetimes were considered former smokers
if they answered negatively to the question “Do you smoke
now?” and current smokers if they answered aﬃrmatively.
Using height and weight measured during the study exam-
ination, body mass index (BMI) was calculated as weight in
kilograms divided by height in meters squared.
Rigorous procedures with quality control checks were
used in blood collection and details about these proce-
dures are provided in the NHANES Laboratory/Medical
Technologists Procedures Manual [8, 11]. Measurement
of plasma leptin was performed by Linco Research, Inc.,
St. Louis, Mo, USA. The assay was a radioimmunoassay
(RIA) with a polyclonal antibody raised in rabbits against
highly puriﬁed recombinant human leptin. The minimum
detectable concentration of the assay was 0.5Fg/L leptin,
and the limit of linearity was 100Fg/L. Recovery of leptin
added to serum is 99–104% over the linear range of the assay.
The RIA agrees reasonable well with rough quantiﬁcation by
Western blot. Within- and between-assay CVs ranged from
3.4% to 8.3% and from 3.6% to 6.2%, respectively [11, 12].
Serum total cholesterol was measured enzymatically at
the Johns Hopkins Lipid Laboratory. Serum glucose was
measured using the modiﬁed hexokinase method at the Uni-
versity of Missouri Diabetes Diagnostic Laboratory. Diabetes
wasdeﬁnedbasedontheguidelinesoftheAmericanDiabetes
Association as a serum glucose ≥126mg/dL after fasting
for a minimum of 8 hours, a serum glucose ≥200mg/dL
for those who fasted <8 hours before their NHANES
visit, a glycosylated hemoglobin value ≥6.5%, or a self-
reported current use of oral hypoglycemic medication or
insulin. Seated systolic and diastolic blood pressures were
measured using a mercury sphygmomanometer according
to the American Heart Association and Seventh Joint
National Committee (JNC7) recommendations [17]. Up to
3 measurements were averaged for systolic and diastolic
pressures. Participants were considered to have hypertension
if they reported current blood pressure-reducing medication
use and/or had systolic blood pressure ≥140mm Hg and/or
diastolic blood pressure ≥90mm Hg [17].
2.3. Statistical Analysis. Plasma leptin was analyzed both as
ac o n t i n u o u sv a r i a b l ea sw e l la sac a t e g o r i c a lv a r i a b l e .F o r
the analysis as a continuous variable, leptin values were
log transformed (base e) as a result of their skewed distri-
bution. Using the distribution present in the NHANES III
population, we categorized plasma leptin level into quartiles
(≤4.3Fg/L, 4.4–8.7Fg/L, 8.8–16.9Fg/L, >16.9Fg/L). The
multivariable-adjusted odds ratio [(OR) (95% conﬁdence
interval (CI)] of CKD associated with leptin quartile was
calculated with the lowest quartile as the referent, using
logistic regression models. Odds ratios were calculated
initially after age and sex adjustment and subsequently after
additionaladjustingforrace/ethnicity(non-Hispanicwhites,
non-Hispanic blacks, Mexican Americans, and others), edu-
cationcategories(belowhighschool,highschool,abovehigh
school), smoking (never smoker, former smoker, current
smoker), alcohol intake (continuous), BMI (continuous),
diabetes mellitus (absent, present), hypertension (absent,
present), and total serum cholesterol (continuous). Trends
in the OR of CKD across increasing plasma leptin category
were determined by modeling median within-quartile leptinInternational Journal of Nephrology 3
level as a continuous variable. To examine the dose-response
relationship of the observed association between plasma
leptin level and CKD without linearity assumptions, we used
ﬂexible nonparametric logistic regression employing the
generalized additive modeling approach (R system for sta-
tistical computing, available from Comprehensive R Archive
Network [http://www.cran.r-project.org/]) to calculate odds
ratio of CKDs mellitus, adjusting for all covariates in the
multivariable model; the predicted odds ratio of CKD was
thenplottedagainstincreasingleptinlevels(onthelogscale).
Previous studies have shown that serum leptin levels are
associated with increased systemic inﬂammation as mea-
sured by C-reactive protein levels [18], hyperglycemia [12],
high insulin levels [19], and increased systolic blood pressure
[20], factors that have also been shown to be associated with
CKD[17, 21, 22]. Therefore, in a supplementary analysis, to
examine if the observed association between plasma leptin
and CKD was explained by C-reactive protein levels, fasting
insulin, glucose levels, or systolic blood pressure, we adjusted
for these variables in the multivariable-adjusted model.
Sampleweights[9]thataccountfortheunequalprobabilities
ofselection,oversampling,andnonresponsewereappliedfor
all analyses using SUDAAN (version 8.0; Research Triangle
Institute, Research Triangle Park, NC) and SAS (version 9.2;
SAS Institute, Cary, NC) software; Standard errors (SE) were
estimated using the Taylor series linearization method.
3. Results
Table 1 presents the characteristics of the study population
included in the current analysis. Overall, this study included
a broad age range, multiethnic sample of Americans with an
approximately equal number of men and women. The mean
eGFR of the study participants was 94mL/min/1.73m2,a n d
3.5% had CKD.
Table 2 presents the association between quartile of
plasma leptin and CKD. A positive association between
higher leptin quartiles and CKD was present in the age, sex-
adjusted model as well as the multivariable model. When
analyzed as a continuous variable after log transformation,
a positive association was present between leptin and CKD.
Table 3 presents the association between plasma leptin
levels and CKD within subgroups deﬁned by gender, BMI
categories, and diabetes and hypertension. Overall, the
association betweenleptin andCKD wasconsistentlypresent
within these subgroups. Although some of the ORs failed
to reach conventional levels of statistical signiﬁcance due to
limited sample size and therefore statistical power, tests for
interaction were not statistically signiﬁcant (each P>0.10
for all stratiﬁed analyses).
Whenweemployednonparametricmodelstographically
examine the dose-response relationship between plasma lep-
tinlevelsandCKDwithoutlinearityassumptionsinvolvedin
traditionalregressionmodels,weobservedanoverallpositive
association between plasma leptin and CKD, consistent with
the results in Tables 1, 2,a n d3. However, there was a steeper
association with CKD for plasma leptin levels >16Fg/L
(Figure 1).
Table 1: Characteristics of the study population (n = 5820).
Characteristics
Mean or
percentage ±
standard error
Age, years 43.1 ±0.5
Women, % 53.6 ±0.9
Race-ethnicity, %
Non-Hispanic whites 77.1 ±1.5
Non-Hispanic blacks 10.3 ±0.7
Mexican Americans 5.1 ±0.5
Other 7.6 ±1.0
Education categories, %
Less than high school 21.5 ±1.1
High school 34.3 ±1.1
More than high school 44.2 ±1.5
Smoking, %
Never 48.3 ±1.0
Former 25.0 ±0.7
Current 26.7 ±1.0
Current alcohol drinker, % 56.1 ±1.7
Body mass index, kg/m2 26.5 ±0.2
Diabetes mellitus, % 5.0 ±0.4
Hypertension, % 28.4 ±1.1
Total cholesterol, mg/dL 203.0 ±0.9
Glomerular ﬁltration rate, mL/min/1.73m2 95.6 ±0.7
Chronic kidney disease, %∗ 3.6 ±0.3
Glucose, mg/dL 98.8 ±0.4
Insulin, uU/mL 10.4 ±0.2
Systolic blood pressure, mmHg 120.8 ±0.5
Diastolic blood pressure, mmHg 73.8 ±0.2
C-reactive protein, mg/dL 0.38 ±0.01
∗Deﬁned as estimated glomerular ﬁltration rate <60mL/min/1.73m2.
In a supplementary analysis, to examine if the observed
association between leptin and CKD was explained by C-
reactive protein, a marker of inﬂammation, or fasting insulin
or glucose levels, or systolic blood pressure, we additionally
adjusted for these variables to the multivariable-adjusted
model. The positive association between leptin and CKD
was attenuated, but still present. Compared to quartile 1 of
plasma leptin (referent), the multivariable OR (95% CI) of
CKD was 1.31 (0.70 to 2.44) in quartile 2, 1.22 (0.57 to
2.62) in quartile 3, and 2.72 (1.14 to 6.48) in quartile 4; P-
trend = 0.0475.
4. Discussion
In a multi-ethnic, population-based sample of US adults, we
found that higher plasma leptin levels were positively associ-
ated with CKD. This association appeared to be independent
of confounders such as age, race-ethnicity, education, BMI,
diabetes, and hypertension and appeared to be consistently
present in both men and women. Furthermore, the observed4 International Journal of Nephrology
Table 2: Association between plasma leptin level and prevalence of chronic kidney disease (CKD).
Plasma leptin
level N CKD
weighted %
Age, sex-adjusted odds
ratio (95% conﬁdence
interval)
Multivariable-adjusted
odds ratio (95% conﬁdence
interval)∗
Quartile 1 (≤4.3
Fg/L) 1453 1.8 1 (referent) 1 (referent)
Quartile 2
(4.4–8.7 Fg/L) 1541 3.21 .42 (0.80 to 2.52) 1.35 (0.73 to 2.52)
Quartile 3
(8.8–16.9 Fg/L) 1464 3.51 .40 (0.74 to 2.62) 1.34 (0.63 to 2.87)
Quartile 4
(>16.9 Fg/L) 1452 6.33 .25 (1.61 to 6.55) 3.31 (1.41 to 7.78)
P-trend 0.0019 0.0135
Log-
transformed
leptin
5820 3.6 1.57 (1.23 to 2.01) 1.74 (1.27 to 2.38)
∗Adjusted for age (years), sex (men, women), race-ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans, others), education categories
(<high school, high school, >high school), smoking (never, former, current), alcohol intake (never, former, current), body mass index (normal, overweight,
obese), diabetes (absent, present), hypertension (absent, present), and serum total cholesterol (mg/dL).
Table 3: Association between plasma leptin level and chronic kidney disease (CKD), by subgroups.
Subgroups of interest No. at
risk
CKD
weighted %
Multivariable-adjusted odds ratio of CKD associated
with log-leptin (95% conﬁdence interval)∗
Age
< 60 4324 0.9 2.06 (1.01 to 4.20)
≥ 60 1496 15.7 1.36 (1.01 to 1.83)
Gender
Men 2627 2.8 1.43 (0.96 to 2.12)
Women 3193 4.3 1.77 (1.09 to 2.88)
Race-ethnicity, %
Non-Hispanic whites 2403 3.9 1.63 (1.10 to 2.41)
Non-Hispanic blacks 1615 2.5 3.31 (1.86 to 5.90)
Mexican Americans,
others 1802 2.5 1.40 (0.80 to 2.45)
Body mass index (BMI)
BMI <25kg/m2 2273 2.9 1.38 (0.62 to 3.07)
25kg/m2 ≤ BMI
<30kg/m2 2058 3.6 2.44 (1.48 to 4.04)
BMI ≥30kg/m2 1489 4.9 3.30 (1.91 to 5.70)
Diabetes
Absent 5358 3.2 1.70 (1.23 to 2.35)
Present 462 10.1 1.41 (0.42 to 4.73)
Hypertension
Absent 3908 1.6 1.42 (0.66 to 3.07)
Present 1912 8.6 1.73 (1.20 to 2.49)
∗Adjusted for age (years), sex (female, male), race-ethnicity (non-Hispanic whites, non-Hispanic blacks, Mexican Americans, others), education categories
(<high school, high school, >high school), smoking (never, former, current), current alcohol intake (absent, present), body mass index (normal, overweight,
obese), diabetes (absent, present), hypertension (absent, present), serum total cholesterol (mg/dL), glucose (mg/dL), insulin (uU/mL) and C-reactive protein
(mg/dL), except the stratifying variable.International Journal of Nephrology 5
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Figure 1: Multivariable-adjusted odds ratio of chronic kidney
disease (CKD) according to plasma leptin level (Fg/L). Solid thick
line represents the predicted odds of CKD from nonparametric
logistic regression; dashed lines, 95% conﬁdence limits for the
nonparametric logistic regression estimates. The nonparametric
logistic regression was adjusted for age (years), sex (men, women),
race-ethnicity(non-Hispanicwhites,non-Hispanicblacks,Mexican
Americans, others), education categories (<high school, high
school, >high school), smoking (never, former, current), body mass
index (normal, overweight, obese), diabetes (absent, present), and
serum total cholesterol (mg/dL). The median value of quartile 1 of
leptin (1.285Fg/L) was used as the referent category to calculate
odds ratios. X axis: plasma leptin level (fg/L) plotted in log scale,
Y1 axis: predicted odds ratio of CKD plotted in log scale, Y2a x i s :
participant number for each serum plasma leptin level.
association between plasma leptin levels and CKD was
present even after adjusting for C-reactive protein and
fasting insulin levels, suggesting an association between this
adipokine and CKD that is independent of these factors.
Several lines of recent evidence suggest that an associa-
tion between leptin and CKD is plausible. This includes the
role of leptin in activating the sympathetic nervous system
and causing chronic elevations in blood pressure and renal
dysfunction [2], inducing natriuresis [3] which may result
in an increase in arterial pressure so as to maintain sodium
and water balance [4], serving as a cofactor of TGF-beta
activation, promoting renal endothelial cell proliferation,
and subsequent glomerulosclerosis [5–7]. It was recently
shown that, in rats, infusion of recombinant leptin caused
the development of focal glomerulosclerosis [5]. Also, leptin
is also reported to be related to insulin resistance [23]a n d
high C-reactive protein levels [24], both of which have been
shown to be related to CKD [21, 25].
There are a few studies in the literature for comparison.
A previous study conducted among women with type 1
diabetes reported that plasma leptin levels are independently
related to reduced renal function [26]. In a study from South
Africa conducted among approximately 300 black subjects,
Okpechi et al. reported that plasma leptin levels were
inversely related to eGFR [27]. In another study, common
polymorphisms in the LEP gene were found to be associated
positively with serum creatinine and inversely with eGFR
[28]. Overall, our ﬁndings of a positive association between
plasma leptin and CKD are in agreement with these previous
studies; in addition, we were able to study a large multiethnic
sample that includes both men and women and also
adjusts for multiple confounders such as BMI, diabetes,
hypertension, lipid levels, and C-reactive protein.
The main strengths of our study include its population-
based nature, inclusion of a representative multiethnic
sample, adequate sample size, and the availability of data
on confounders for multivariable adjustment. Furthermore,
all data were collected following rigorous methodology, in-
cluding a study protocol with standardized quality control
checks. The main limitation of our study is the cross-
sectional nature of NHANES, which precludes conclusions
regarding the temporal nature of the association between
plasma leptin and CKD. Second, deﬁning CKD as eGFR
<60mL/min/1.73m2 introduces some ascertainment bias.
This bias is likely to result in under- or overestimation of
odds ratios presented in this report.
In summary, in a multiethnic sample of US adults,
we found that higher plasma leptin levels are associated
with CKD, independent of traditional factors such as age,
sex, smoking, alcohol intake, BMI, diabetes, hypertension
and serum cholesterol. Our results suggest that leptin may
explain part of the reported association between obesity and
kidney disease. However, future prospective cohort studies
are needed to conﬁrm or refute our ﬁndings.
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